PK 071
Alternative Names: PK-071Latest Information Update: 26 Sep 2023
At a glance
- Originator PharmaKure
- Class Antidementias; Antidepressants; Antipsychotics; Neuroprotectants
- Mechanism of Action Alpha-synuclein degraders; Amyloid beta-protein modulators; Tau protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Alzheimer's disease; Multiple system atrophy
Most Recent Events
- 22 Sep 2023 Early research in Alzheimer's disease in USA (PO), prior to September 2023 (PharmaKure pipeline, September 2023)
- 22 Sep 2023 Early research in Multiple system atrophy in USA (PO) prior to September 2023 (PharmaKure pipeline, September 2023)
- 22 Sep 2023 PharmaKure plans a phase I/II trial for Multiple system atrophy and Alzheimer's disease (PharmaKure pipeline, September 2023)